Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5560)
All Articles published online
|
Mar 10, 2011 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Perri F, Lorenzo GD, Scarpati GDV, Buonerba C. Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options. World J Clin Oncol 2011; 2(3): 150-157 [PMID: 21611089 DOI: 10.5306/wjco.v2.i3.150] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v2/i3/150.htm |
| Number | Citing Articles |
| 1 |
Zubair W Baloch, Virginia A LiVolsi. Special types of thyroid carcinoma. Histopathology 2018; 72(1): 40 doi: 10.1111/his.13348
|
| 2 |
Makoto Tahara, Naomi Kiyota, Tomoko Yamazaki, Naoko Chayahara, Kenji Nakano, Lina Inagaki, Kazuhisa Toda, Tomohiro Enokida, Hironobu Minami, Yoshinori Imamura, Tatsuya Sasaki, Takuya Suzuki, Katsuki Fujino, Corina E. Dutcus, Shunji Takahashi. Lenvatinib for Anaplastic Thyroid Cancer. Frontiers in Oncology 2017; 7 doi: 10.3389/fonc.2017.00025
|
| 3 |
Laurence Faugeras, Anne-Sophie Pirson, Julian Donckier, Luc Michel, Julien Lemaire, Sebastien Vandervorst, Lionel D’Hondt. Refractory thyroid carcinoma: which systemic treatment to use?. Therapeutic Advances in Medical Oncology 2018; 10: 175883401775285 doi: 10.1177/1758834017752853
|
| 4 |
Matthias Lang, Thomas Longerich, Chrysanthi Anamaterou. Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer. Thyroid Research 2023; 16(1) doi: 10.1186/s13044-023-00147-7
|
| 5 |
LORENZO ALLEGRI, FEDERICA BALDAN, CATIA MIO, CINZIA PUPPIN, DIEGO RUSSO, VLADIMIR KRYŠTOF, GIUSEPPE DAMANTE. Effects of BP-14, a novel cyclin-dependent kinase inhibitor, on anaplastic thyroid cancer cells. Oncology Reports 2016; 35(4): 2413 doi: 10.3892/or.2016.4614
|
| 6 |
Enrique Grande, Juan José Díez, Carles Zafon, Jaume Capdevila. Thyroid Cancer: Molecular Aspects and New Therapeutic Strategies. Journal of Thyroid Research 2012; 2012: 1 doi: 10.1155/2012/847108
|
| 7 |
Kunal Ramesh Chandekar, Swayamjeet Satapathy, Chandrasekhar Bal. Positron Emission Tomography/Computed Tomography in Thyroid Cancer. PET Clinics 2024; 19(2): 131 doi: 10.1016/j.cpet.2023.12.001
|
| 8 |
Gheysen Laetitia, Saussez Sven, Journe Fabrice. Combinatorial Therapies in Thyroid Cancer: An Overview of Preclinical and Clinical Progresses. Cells 2020; 9(4): 830 doi: 10.3390/cells9040830
|
| 9 |
Judy Jin, Roy Phitayakorn, Scott M. Wilhelm, Christopher R. McHenry. Advances in management of thyroid cancer. Current Problems in Surgery 2013; 50(6): 241 doi: 10.1067/j.cpsurg.2013.02.001
|
| 10 |
A. L. Pylev, A. A. Zhandarova, K. S. Petrov, D. S. Romanov, V. A. Lisovoy, S. V. Golub. Anaplastic thyroid cancer. Is there a light at the end of the tunnel?. Head and Neck Tumors (HNT) 2020; 10(1): 10 doi: 10.17650/2222-1468-2020-10-1-10-19
|
| 11 |
Gautham Chengizkhan, Bharti Bisht, Sridhar Muthusami, Muralidharan Anbalagan, Ilangovan Ramachandran, R. Ileng Kumaran. Cancer Stem Cells: New Horizons in Cancer Therapies. 2020; : 15 doi: 10.1007/978-981-15-5120-8_2
|
| 12 |
Esther Diana Rossi, William C. Faquin, Liron Pantanowitz. Aggressive Variants of Follicular- and Parafollicular-Derived Thyroid Carcinoma. AJSP: Reviews and Reports 2019; 24(2): 61 doi: 10.1097/PCR.0000000000000297
|
| 13 |
Ling Ma, Qiao Cheng. Inhibiting 6-phosphogluconate dehydrogenase reverses doxorubicin resistance in anaplastic thyroid cancer via inhibiting NADPH-dependent metabolic reprogramming. Biochemical and Biophysical Research Communications 2018; 498(4): 912 doi: 10.1016/j.bbrc.2018.03.079
|
| 14 |
|
| 15 |
Qingan Yu, Wenjing Jiang, Dan Li, Mingqi Gu, Kunpeng Liu, Liqian Dong, Chaoqun Wang, Hongchi Jiang, Wenjie Dai. Sodium orthovanadate inhibits growth and triggers apoptosis of human anaplastic thyroid carcinoma cells in vitro and in�vivo. Oncology Letters 2019; doi: 10.3892/ol.2019.10090
|
| 16 |
CHENGHAI WANG, SIJIA LU, JIXIN JIANG, XIAOQIN JIA, XIAOYUN DONG, PING BU. Hsa-microRNA-101 suppresses migration and invasion by targeting Rac1 in thyroid cancer cells. Oncology Letters 2014; 8(4): 1815 doi: 10.3892/ol.2014.2361
|
| 17 |
Robert I Haddad, Lindsay Bischoff, Douglas Ball, Victor Bernet, Erik Blomain, Naifa Lamki Busaidy, Michael Campbell, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Whitney S. Goldner, Theresa Guo, Megan Haymart, Shelby Holt, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Dominick M. Lamonica, Susan Mandel, Stephanie Markovina, Bryan McIver, Christopher D. Raeburn, Rod Rezaee, John A. Ridge, Mara Y. Roth, Randall P. Scheri, Jatin P. Shah, Jennifer A. Sipos, Rebecca Sippel, Cord Sturgeon, Thomas N. Wang, Lori J. Wirth, Richard J. Wong, Michael Yeh, Carly J. Cassara, Susan Darlow. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network 2022; 20(8): 925 doi: 10.6004/jnccn.2022.0040
|
| 18 |
Yihui Lin, Jianjia Jiang. Long non-coding RNA LINC00704 promotes cell proliferation, migration, and invasion in papillary thyroid carcinoma via miR-204-5p/HMGB1 axis. Open Life Sciences 2020; 15(1): 561 doi: 10.1515/biol-2020-0057
|
| 19 |
Luisa Vicari, Cristina Colarossi, Dario Giuffrida, Ruggero De Maria, Lorenzo Memeo. Cancer stem cells as a potential therapeutic target in thyroid carcinoma. Oncology Letters 2016; 12(4): 2254 doi: 10.3892/ol.2016.4936
|
| 20 |
Oussama ElMokh, Dorothée Ruffieux-Daidié, Matthias A. Roelli, Amandine Stooss, Wayne A. Phillips, Jürg Gertsch, Matthias S. Dettmer, Roch-Philippe Charles. Combined MEK and Pi3′-kinase inhibition reveals synergy in targeting thyroid cancer in vitro and in vivo. Oncotarget 2017; 8(15): 24604 doi: 10.18632/oncotarget.15599
|
| 21 |
Christine Dierks, Dirk Vordermark, Kerstin Lorenz. Neuerungen in der Systemtherapie des Anaplastischen Schilddrüsenkarzinoms. TumorDiagnostik & Therapie 2022; 43(06): 375 doi: 10.1055/a-1744-2100
|
| 22 |
Aurora Mirabile, Matteo Biafora, Leone Giordano, Gianluigi Arrigoni, Maria Giulia Cangi, Italo Dell’Oca, Francesca Lira Luce, Davide Di Santo, Andrea Galli, Michele Tulli, Renata Mellone, Davide Valsecchi, Vanesa Gregorc, Mario Bussi. Uncommon Site of Metastasis and Prolonged Survival in Patients with Anaplastic Thyroid Carcinoma: A Systematic Review of the Literature. Cancers 2020; 12(9): 2585 doi: 10.3390/cancers12092585
|
| 23 |
Zubair W. Baloch, Virginia A. LiVolsi. Thyroid Cancer. 2016; : 935 doi: 10.1007/978-1-4939-3314-3_96
|
| 24 |
Magdalena Rudzińska, Barbara Czarnocka. The Impact of Transcription Factor Prospero Homeobox 1 on the Regulation of Thyroid Cancer Malignancy. International Journal of Molecular Sciences 2020; 21(9): 3220 doi: 10.3390/ijms21093220
|
| 25 |
Luca Hegedűs, Dominika Rittler, Tamás Garay, Paul Stockhammer, Ildikó Kovács, Balázs Döme, Sarah Theurer, Thomas Hager, Thomas Herold, Stavros Kalbourtzis, Agnes Bankfalvi, Kurt W. Schmid, Dagmar Führer, Clemens Aigner, Balázs Hegedűs. HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic Thyroid Cancer Cell Line. Pathology & Oncology Research 2020; 26(4): 2523 doi: 10.1007/s12253-020-00834-y
|
| 26 |
Matthias A. Roelli, Dorothée Ruffieux-Daidié, Amandine Stooss, Oussama ElMokh, Wayne A. Phillips, Matthias S. Dettmer, Roch-Philippe Charles. PIK3CAH1047R-induced paradoxical ERK activation results in resistance to BRAFV600E specific inhibitors in BRAFV600E PIK3CAH1047R double mutant thyroid tumors. Oncotarget 2017; 8(61): 103207 doi: 10.18632/oncotarget.21732
|
| 27 |
Denise Lovison, Lorenzo Allegri, Federica Baldan, Maurizio Ballico, Giuseppe Damante, Christian Jandl, Walter Baratta. Cationic carboxylate and thioacetate ruthenium(ii) complexes: synthesis and cytotoxic activity against anaplastic thyroid cancer cells. Dalton Transactions 2020; 49(24): 8375 doi: 10.1039/D0DT01390K
|
| 28 |
Marilena Celano, Valentina Maggisano, Roberta Francesca De Rose, Stefania Bulotta, Jessica Maiuolo, Michele Navarra, Diego Russo. Flavonoid Fraction of Citrus Reticulata Juice Reduces Proliferation and Migration of Anaplastic Thyroid Carcinoma Cells. Nutrition and Cancer 2015; 67(7): 1183 doi: 10.1080/01635581.2015.1073760
|
| 29 |
Chuanzheng Sun, Chao Li, Zedong Hu, Xiaojiang Li, Jiehua He, Ming Song, Guojun Li, Fenghua Zhang, Qiuli Li. Influence of risk grouping on therapeutic decisions in patients with anaplastic thyroid carcinoma. European Archives of Oto-Rhino-Laryngology 2015; 272(4): 985 doi: 10.1007/s00405-014-2937-2
|
| 30 |
Zubair Baloch, Virginia A LiVolsi, Rashmi Tondon. Aggressive variants of follicular cell derived thyroid carcinoma; the so called ‘Real Thyroid Carcinomas’. Journal of Clinical Pathology 2013; 66(9): 733 doi: 10.1136/jclinpath-2013-201626
|
| 31 |
Eun Mee Oh, Kyu Eun Lee, Hyungju Kwon, Eun Young Kim, Dong Sik Bae, Yeo-Kyu Youn. Analysis of patients with anaplastic thyroid cancer expected to have curative surgery. Journal of the Korean Surgical Society 2012; 83(3): 123 doi: 10.4174/jkss.2012.83.3.123
|
| 32 |
Gennaro Di Maro, Francesca Maria Orlandella, Tammaro Claudio Bencivenga, Paolo Salerno, Clara Ugolini, Fulvio Basolo, Roberta Maestro, Giuliana Salvatore. Identification of Targets of Twist1 Transcription Factor in Thyroid Cancer Cells. The Journal of Clinical Endocrinology & Metabolism 2014; 99(9): E1617 doi: 10.1210/jc.2013-3799
|
| 33 |
Ulrike Hinterseher, Annette Wunderlich, Silvia Roth, Annette Ramaswamy, Detlef K. Bartsch, Stefan Hauptmann, Brandon H. Greene, Volker Fendrich, Sebastian Hoffmann. Expression of hedgehog signalling pathway in anaplastic thyroid cancer. Endocrine 2014; 45(3): 439 doi: 10.1007/s12020-013-0015-y
|
| 34 |
Francesco Perri, Antonio Giordano, Salvatore Pisconti, Franco Ionna, Maria G. Chiofalo, Francesco Longo, Davide Leopardo, Giuseppina Della Vittoria Scarpati, Luciano Pezzullo. Thyroid cancer management. Anti-Cancer Drugs 2018; 29(6): 483 doi: 10.1097/CAD.0000000000000617
|
| 35 |
Xiawei Shen, Yali Zhu, Zuixuan Xiao, Xuemei Dai, Dan Liu, Lin Li, Baolai Xiao. Antiviral Drug Ribavirin Targets Thyroid Cancer Cells by Inhibiting the eIF4E-β-Catenin Axis. The American Journal of the Medical Sciences 2017; 354(2): 182 doi: 10.1016/j.amjms.2017.03.025
|
| 36 |
Alessio Terenzi, Laura Tomasello, Angelo Spinello, Giuseppe Bruno, Carla Giordano, Giampaolo Barone. (Dipyrido[3,2-a:2′,3′-c]phenazine)(glycinato)copper(II) perchlorate: A novel DNA-intercalator with anti-proliferative activity against thyroid cancer cell lines. Journal of Inorganic Biochemistry 2012; 117: 103 doi: 10.1016/j.jinorgbio.2012.08.011
|
| 37 |
Lisa M. Greene, Niamh M. O’Boyle, Derek P. Nolan, Mary J. Meegan, Daniela M. Zisterer. The vascular targeting agent Combretastatin-A4 directly induces autophagy in adenocarcinoma-derived colon cancer cells. Biochemical Pharmacology 2012; 84(5): 612 doi: 10.1016/j.bcp.2012.06.005
|
| 38 |
Natalie M. Lowe, Sean Loughran, Nicholas J. Slevin, Beng K. Yap. Anaplastic Thyroid Cancer: The Addition of Systemic Chemotherapy to Radiotherapy Led to an Observed Improvement in Survival—A Single Centre Experience and Review of the Literature. The Scientific World Journal 2014; 2014: 1 doi: 10.1155/2014/674583
|
| 39 |
Christine Dierks. Systemtherapie des anaplastischen Schilddrüsenkarzinoms. Die Onkologie 2022; 28(8): 642 doi: 10.1007/s00761-022-01198-5
|
| 40 |
John C. Deutsch. Gastrointestinal Endoscopy in the Cancer Patient. 2013; : 327 doi: 10.1002/9781118555651.ch31
|
| 41 |
Christina A von Roemeling, John A Copland. Targeting lipid metabolism for the treatment of anaplastic thyroid carcinoma. Expert Opinion on Therapeutic Targets 2016; 20(2): 159 doi: 10.1517/14728222.2016.1086341
|
| 42 |
Suresh Chandra Sharma, Pirabu Sakthivel, Sarath Raveendran, Chirom Amit Singh, Tripti Nakra, Shipra Agarwal. Anaplastic Carcinoma Thyroid in a Young Child – an Extremely Rare Occurrence. Acta Medica (Hradec Kralove, Czech Republic) 2018; 61(4): 150 doi: 10.14712/18059694.2018.134
|
| 43 |
Valeria G. Antico Arciuch, Marika A. Russo, Mariavittoria Dima, Kristy S. Kang, Florence Dasrath, Xiao-Hui Liao, Samuel Refetoff, Cristina Montagna, Antonio Di Cristofano. Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors. Oncotarget 2011; 2(12): 1109 doi: 10.18632/oncotarget.380
|
| 44 |
Ling Ma, Honghua Fei. Antimalarial drug artesunate is effective against chemoresistant anaplastic thyroid carcinoma via targeting mitochondrial metabolism. Journal of Bioenergetics and Biomembranes 2020; 52(2): 123 doi: 10.1007/s10863-020-09824-w
|
| 45 |
S. Lopes-Ventura, M. Pojo, A. T. Matias, M. M. Moura, I. J. Marques, V. Leite, B. M. Cavaco. The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines. Journal of Endocrinological Investigation 2019; 42(5): 527 doi: 10.1007/s40618-018-0947-4
|
| 46 |
Ricardo R. Lastra, Virginia A. LiVolsi, Zubair W. Baloch. Aggressive variants of follicular cell‐derived thyroid carcinomas: A cytopathologist's perspective. Cancer Cytopathology 2014; 122(7): 484 doi: 10.1002/cncy.21417
|
| 47 |
Elisa Stellaria Grassi, Viola Ghiandai, Luca Persani. Thyroid Cancer Stem-Like Cells: From Microenvironmental Niches to Therapeutic Strategies. Journal of Clinical Medicine 2021; 10(7): 1455 doi: 10.3390/jcm10071455
|
| 48 |
Jing Liu, Liguo Feng, Haitao Zhang, Jin Zhang, Yanyan Zhang, Shujing Li, Long Qin, Ziyao Yang, Jianxia Xiong. Effects of miR-144 on the sensitivity of human anaplastic thyroid carcinoma cells to cisplatin by autophagy regulation. Cancer Biology & Therapy 2018; 19(6): 484 doi: 10.1080/15384047.2018.1433502
|
| 49 |
Ying Wang, Zhigang Hu, Weiyuan Ma, Yong Niu, Jingwei Su, Lingxiang Zhang, Pengxin Zhao. Signal transducer and activator of transcription 3 inhibition alleviates resistance to BRAF inhibition in anaplastic thyroid cancer. Investigational New Drugs 2021; 39(3): 764 doi: 10.1007/s10637-020-01024-y
|
| 50 |
Emi Date, Kunio Okamoto, Souichi Fumita, Hiroyasu Kaneda. Gastrointestinal perforation related to lenvatinib, an anti-angiogenic inhibitor that targets multiple receptor tyrosine kinases, in a patient with metastatic thyroid cancer. Investigational New Drugs 2018; 36(2): 350 doi: 10.1007/s10637-017-0522-4
|
| 51 |
Enrico Maria Amadei, Laura Benedettini, Ottavio Piccin. Two Cases of Cervical Hemorrhage with Upper Airway Obstruction: A Life-Threatening Condition. Case Reports in Medicine 2014; 2014: 1 doi: 10.1155/2014/674176
|
| 52 |
Yi-Tian Li, Xiao-Ting Tian, Mo-Li Wu, Xu Zheng, Qing-You Kong, Xiao-Xin Cheng, Guang-Wen Zhu, Jia Liu, Hong Li. Resveratrol Suppresses the Growth and Enhances Retinoic Acid Sensitivity of Anaplastic Thyroid Cancer Cells. International Journal of Molecular Sciences 2018; 19(4): 1030 doi: 10.3390/ijms19041030
|
| 53 |
Hilda Samimi, Rezvan Tavakoli, Parviz Fallah, Alireza Naderi Sohi, Maryam Amini Shirkouhi, Mahmood Naderi, Vahid Haghpanah. BI-847325, a selective dual MEK and Aurora kinases inhibitor, reduces aggressive behavior of anaplastic thyroid carcinoma on an in vitro three-dimensional culture. Cancer Cell International 2022; 22(1) doi: 10.1186/s12935-022-02813-6
|
| 54 |
Kun Hu, Juan Zhang, Min Yu, Chang'e Xiong. Inhibition of Mnk–eIF4E pathway sensitizes the efficacy to chemotherapy in anaplastic thyroid cancer. Future Oncology 2017; 13(6): 489 doi: 10.2217/fon-2016-0320
|
| 55 |
Haoran Feng, Xi Cheng, Jie Kuang, Lingxie Chen, Stanley Yuen, Minmin Shi, Juyong Liang, Baiyong Shen, Zhijian Jin, Jiqi Yan, Weihua Qiu. Apatinib-induced protective autophagy and apoptosis through the AKT–mTOR pathway in anaplastic thyroid cancer. Cell Death & Disease 2018; 9(10) doi: 10.1038/s41419-018-1054-3
|
| 56 |
Julie Bolin. Thyroid Follicular Epithelial Cell–Derived Cancer: New Approaches and Treatment Strategies. Journal of Nuclear Medicine Technology 2021; 49(3): 199 doi: 10.2967/jnmt.120.257105
|
| 57 |
Manoj Garg, Deepika Kanojia, Anand Mayakonda, Trivadi S Ganesan, Bindhya Sadhanandhan, Sidhanth Suresh, Sneha S., Rohit P. Nagare, Jonathan W. Said, Ngan B. Doan, Ling-Wen Ding, Erkan Baloglu, Sharon Shacham, Michael Kauffman, H. Phillip Koeffler. Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-10325-x
|
| 58 |
Dongbin Ahn, Jin Ho Sohn. Anaplastic Thyroid Carcinoma: Experience of a Single Institute. Korean Journal of Otorhinolaryngology-Head and Neck Surgery 2012; 55(1): 37 doi: 10.3342/kjorl-hns.2012.55.1.37
|
| 59 |
Anne-Katrin Dumke, Tanja Pelz, Dirk Vordermark. Long-term results of radiotherapy in anaplastic thyroid cancer. Radiation Oncology 2014; 9(1) doi: 10.1186/1748-717X-9-90
|
| 60 |
Xiayun He, Duanshu Li, Chaosu Hu, Zhuoying Wang, Hongmei Ying, Yi Wu. Outcome after intensity modulated radiotherapy for anaplastic thyroid carcinoma. BMC Cancer 2014; 14(1) doi: 10.1186/1471-2407-14-235
|
| 61 |
Vincenzo Marotta, Maria Domenica Franzese, Michela Del Prete, Maria Grazia Chiofalo, Valeria Ramundo, Raffaella Esposito, Francesca Marciello, Luciano Pezzullo, Annachiara Carratù, Mario Vitale, Annamaria Colao, Antongiulio Faggiano. Targeted therapy with kinase inhibitors in aggressive endocrine tumors. Expert Opinion on Pharmacotherapy 2013; 14(9): 1187 doi: 10.1517/14656566.2013.796931
|
| 62 |
Fundamentals of Cancer Detection, Treatment, and Prevention. 2022; : 395 doi: 10.1002/9783527838561.ch18
|
| 63 |
Haralabos Koussis, Carlo Alberto Giorgi, Elisabetta Di Liso, Maria Concetta Carlucci, Ambrogio Fassina, Gino Marioni, Pier Franco Conte. Complete response to weekly carboplatin–docetaxel chemotherapy in a 91-year-old woman with anaplastic thyroid cancer. American Journal of Otolaryngology 2015; 36(2): 268 doi: 10.1016/j.amjoto.2014.03.006
|
| 64 |
Mathias Montenarh, Nathaniel E. B. Saidu. The Effect of Diallyl Polysulfanes on Cellular Signaling Cascades. Natural Product Communications 2012; 7(3): 1934578X1200700 doi: 10.1177/1934578X1200700324
|
| 65 |
Catia Mio, Elisa Lavarone, Ketty Conzatti, Federica Baldan, Barbara Toffoletto, Cinzia Puppin, Sebastiano Filetti, Cosimo Durante, Diego Russo, Arturo Orlacchio, Antonio Di Cristofano, Carla Di Loreto, Giuseppe Damante. MCM5 as a target of BET inhibitors in thyroid cancer cells. Endocrine-Related Cancer 2016; 23(4): 335 doi: 10.1530/ERC-15-0322
|